Australia markets closed

Bausch + Lomb Corporation (BLCO)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
17.60+0.28 (+1.62%)
At close: 04:00PM EST
17.25 -0.35 (-1.99%)
After hours: 07:46PM EST

Bausch + Lomb Corporation

520 Applewood Crescent
Vaughan, ON L4K 4B4
Canada

https://www.bausch.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full-time employees13,300

Key executives

NameTitlePayExercisedYear born
Mr. Osama A. EldessoukyExecutive VP & CFO1.09MN/A1972
Dr. Yehia Hashad M.D.Executive VP of Research & Development and Chief Medical officer1.09MN/A1967
Mr. Brenton L. Saunders J.D.CEO & ChairmanN/AN/A1970
Mr. Alan Waterhouse CPFA, MBAExecutive VP and Chief Supply Chain & Operations OfficerN/AN/A1960
Mr. Frederick J. MunschSenior VP, Controller & Chief Accounting OfficerN/AN/A1970
Mr. A. Robert D. BaileyExecutive VP & Chief Legal OfficerN/AN/A1963
Mr. Jonathon L. KellermanChief Compliance OfficerN/AN/AN/A
T.J. CrawfordChief Communications OfficerN/AN/AN/A
Dr. Manisha A. Narasimhan Ph.D.Chief Corporate Development & Digital OfficerN/AN/A1977
Ms. Asli GevgililiExecutive VP & Chief Human Resources OfficerN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products for therapeutic use, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, dry eye, and redness relief. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Corporate governance

Bausch + Lomb Corporation’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.